Pay in 4 interest-free payments of $33.27 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
placebo-controlled Phase 1/2a trial for patients with open angle glaucoma or ocular hypertension
Chemical Name: ethyl(3R
Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil
InChi: InChI=1S/C18H31NO4
LGK974 potently inhibits Wnt signaling in vitro and in vivo
Istaroxime Catalog No.:M9594-10 placebo-controlled Phase 1/2a trial forIstaroxime, also known as PST 2744, is a positive inotropic agent that mediates its action through inhibition of sodium potassium adenosine triphosphatase (Na+ K+ ATPase). Na+ K+ ATPase inhibition increases intracellular sodium levels, which reverses the driving force of the sodium calcium exchanger, inhibiting calcium extrusion and possibly facilitating calcium entry. Additionally, Istaroxime increases intracellular calcium by improving the efficacy